Barbara J. Anderson, Ph.D.
Dr. Anderson is involved in clinical research projects relating to family and developmental factors impacting psychological and physical health outcomes in youth with Type I and Type II diabetes.
Sheila K. Gunn, M.D.
Dr. Gunn’s research interest involves participation in the TODAY study, a multicenter, national study investigating treatment regimens for adolescent patients with Type 2 diabetes. This study involves several treatment regimens of medications, diet and exercise with both short and long term outcome measures. She is a member of the Texas Children's Hosptial Gender Medicine team developing Optimal Treatment Guidelines for Care and investigating diagnosis, endocrine treatment, genetics and psychological factors in disorders of sexual development. The gender Medicine team is also investigating diagnostic factors for non classic Congential Adrenal Hyperplasia.
Morey W. Haymond,M.D.
Dr. Haymond’s primary area of investigation has been the hormonal regulation of nutrient oxidation and metabolic control of glucose and protein metabolism. He has been instrumental in the development of models to measure in vivo rates of protein synthesis, proteolysis, glucose production and gluconeogenesis using stable isotopic tracers. Dr. Haymond has and continues to apply these methods and develop a number of other methods and models. Since then, he has carried out a number of investigations in a variety of conditions examining the mechanism of glucose and substrate regulation in a variety of medical conditions in infants and children and investigated the impact of a variety of glucoregulatory hormones on amino acid and glucose homeostasis. He has been instrumental in the development of new models and methods to quantitate in vivo rates of gluconeogenesis which now permit such studies in mice and all ages of humans. With a better understanding of the factors that impact the regulation of glucose homeostasis in the diabetic, the hypoglycemic, and normal child, better strategies and new therapeutic interventions to normalize glucose homeostasis in both the conditions of hyper- and hypoglycemia may be developed. Dr. Haymond is actively exploring the regulation of glucose production and gluconeogenesis in normal children and in children with Type I and Type II diabetes and obesity. In addition, he is studying the metabolic and molecular regulation of human lactation.
Lefkothea Karaviti, M.D., Ph.D.
Dr. Karaviti has established a consortium and program for gender medicine consisting of members from the Departments of Human Genetics, Psychology, Ethics, Urology, and Gynecology for the management of disorders of sexual differentiation (DSD). Disorders of sex development (DSD) may result in long-lasting physiological and psychological health issues. Health disparities may exist depending upon timing of intervention and adequate hormonal and surgical treatments and psychological counseling. Dr. Karaviti’s clinical research interests include assessment of outcomes of the practice of a multidisciplinary gender medicine team with respect to sex assignment and developing practice guidelines in the area of sexual differentiation disorders. Another area of her clinical research focuses on the study of the developmental aspects of hypospadias and the study of concordance of phenotype genotype in gonadal dysgenesis. Her Gender Medicine practice is based on a multidisciplinary team approach which educates parents and incorporates them into the processes of patient evaluation and decision-making with regards to sex assignment of their child. The team continuously improves the approach to the DSD by studying the concordance between genotype, phenotype and sex assignment.
Jake A. Kushner, M.D.
Dr. Kushner is a diabetes researcher and pediatric endocrinologist who cares for children with type 1 diabetes and cystic fibrosis related diabetes (CFRD). The overarching goal of his NIH-funded basic science research program is to improve outcomes of diabetic patients by promoting regeneration of the insulin-secreting pancreatic beta cells. He studies mitogenic signals, cell cycle regulation, somatic stem cells and the role of aging in islets. His other ongoing studies aim to clarify the molecular basis of CFRD.
Siripoom McKay, M.D.
Dr. McKay is involved in studies of Type II diabetes in children. She is the medical director for the Baylor College of Medicine site of the Treatment Options in Type II Diabetes in Adolescents and Youth. The TODAY study is a National Institutes of Health-sponsored multicenter trial that will determine which of three treatment options (metformin alone, metformin plus intensive lifestyle changes, and metformin plus rosiglitazone) best maintains glycemic control in children with Type II diabetes. Other projects examine the ethnic differences in comorbidities in children with Type II diabetes and the effect of exercise on fuel utilization in children with Type II diabetes. Dr. McKay is also a co-investigator on a study to see whether teaching parents problem-solving strategies can improve the glycemic control in a child with Type I diabetes.
Maria J. Redondo, M.D.
Dr. Redondo’s research interest is the pathogenesis of pediatric diabetes. She conducted seminal genetic studies in twins of patients, and on the influence of HLA genotypes on progression to type 1 diabetes in subjects at risk. Dr. Redondo’s current area of investigation is the identification of genetic and environmental factors, such as those associated with obesity, that influence beta-cell destruction in children with new onset type 1 diabetes. The goal of this research is to develop novel strategies to preserve beta cell function and thus decrease the risk of diabetic complications in patients and, ultimately, prevent development of type 1 diabetes in healthy subjects. In addition, Dr. Redondo is the principal investigator at Texas Children’s Hospital for TrialNet, a NIDDK-sponsored, an international study to evaluate factors that determine development of type 1 diabetes, and to conduct clinical trials to prevent this disease in subjects at risk. She is also an investigator at T1DExchange Clinic Network, an integrated Clinic Network of over 65 clinics across the United States with the goal to accelerate all aspects of therapy and research for type 1 diabetes. Dr. Redondo is also actively involved in the Pediatric Diabetes Consortium (PDC), a consortium of seven pediatric diabetes centers in the United States for the sharing of information and the development of joint research projects. Finally, Dr. Redondo is interested in the behavioral aspects that impact clinical outcomes in children and adolescents with diabetes. She is one of the endocrine mentors in the NIH-sponsored “Mentoring Behavioral Scientists for Career Development in Pediatric T1D [type 1 diabetes] Research” career development program (Principal Investigator: Dr. Barbara Anderson). Dr. Redondo’s clinical interest is pediatric diabetes, including type 1, type 2, monogenic (MODY) and atypical forms of diabetes. Dr. Redondo’s clinical goal is to improve the lives of children with diabetes through a family-centered approach and the use of technology.